Comment
Author: Admin | 2025-04-28
PH ≤4. Darkening of solutions indicate degradation. Do not heat-sterilize.Oral:Extended release: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect capsules from light and moisture.Immediate release: Store at 20°C to 25°C (68°F to 77°F). Protect from moisture.Suppositories: Store at 20°C to 25°C (68°F to 77°F). Morphine (Systemic) Images morphine 30 mg morphine 15 mg morphine 200 mg morphine 30 mg morphine 60 mg morphine 100 mg Drug InteractionsAlfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapyAlizapride: May enhance the CNS depressant effect of CNS Depressants. Monitor therapyAlvimopan: Opioid Agonists may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Consider therapy modificationAmifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered. Consider therapy modificationAmphetamines: May enhance the analgesic effect of Opioid Agonists. Monitor therapyAnticholinergic Agents: May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. Monitor therapyAntiplatelet Agents (P2Y12 Inhibitors): Morphine (Systemic) may diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Systemic) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown. Exceptions: Cangrelor. Consider therapy modificationAzelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). Avoid combinationBlonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Consider therapy modificationBlood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents. Monitor therapyBrimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Monitor therapyBrimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapyBromopride: May enhance the CNS depressant effect of CNS Depressants. Monitor therapyBromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. Avoid combinationBromperidol: May enhance the CNS depressant effect of CNS Depressants. Avoid combinationCannabidiol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapyCannabis: May enhance the CNS depressant effect of CNS Depressants. Monitor therapyChlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Consider therapy modificationChlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Monitor therapyCNS Depressants: May enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants
Add Comment